Neurotoxicity of amphotericin B methyl ester in dogs

W. G. Ellis, E. Bencken, R. A. LeCouteur, J. R. Barbano, Bruce Wolfe, M. B. Jennings

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Clinical and neuropathologic effects of chronically administered intravenous (iv) amphotericin B methyl ester (AME) were observed in 3 male dogs (2 German shorthaired pointers and 1 pit bull). Each dog received 6.2-7.3 g of AME (299-327 mg/kg body weight) over a period of 11-12 weeks. One dog developed neurologic signs of severe diffuse brain dysfunction and at necropsy all 3 dogs had a marked leukoencephalopathy, most severe in centrum ovale and subcortical white matter of frontal lobes. Brain histopathology included diffuse myelin loss, oligodendrocyte depletion, accumulation of macrophages filled with sudanophilic lipid, fibrillary astrogliosis, and swelling or fragmentation of many axons. Two control dogs administered iv glucose showed no neuropathologic abnormalities. These findings closely resemble the clinical and neuropathologic abnormalities that developed in patients during the first human trial of AME for treatment of fungal infections, but differ from those of animal studies that did not closely simulate the long-term drug administration required for antifungal therapy in humans. It was concluded that before human clinical trial is authorized, experimental protocols for animal studies of drug toxicity should reflect the anticipated human use of the drug, both in dose and duration.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalToxicologic Pathology
Volume16
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Dogs
Brain
Animals
Pharmaceutical Preparations
Macrophages
Toxicity
Swelling
Leukoencephalopathies
Mycoses
Oligodendroglia
Lipids
Glucose
Frontal Lobe
Myelin Sheath
Neurologic Manifestations
Drug-Related Side Effects and Adverse Reactions
Axons
Body Weight
methylamphotericin B
Clinical Trials

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Pathology and Forensic Medicine
  • Toxicology

Cite this

Ellis, W. G., Bencken, E., LeCouteur, R. A., Barbano, J. R., Wolfe, B., & Jennings, M. B. (1988). Neurotoxicity of amphotericin B methyl ester in dogs. Toxicologic Pathology, 16(1), 1-9.

Neurotoxicity of amphotericin B methyl ester in dogs. / Ellis, W. G.; Bencken, E.; LeCouteur, R. A.; Barbano, J. R.; Wolfe, Bruce; Jennings, M. B.

In: Toxicologic Pathology, Vol. 16, No. 1, 1988, p. 1-9.

Research output: Contribution to journalArticle

Ellis, WG, Bencken, E, LeCouteur, RA, Barbano, JR, Wolfe, B & Jennings, MB 1988, 'Neurotoxicity of amphotericin B methyl ester in dogs', Toxicologic Pathology, vol. 16, no. 1, pp. 1-9.
Ellis WG, Bencken E, LeCouteur RA, Barbano JR, Wolfe B, Jennings MB. Neurotoxicity of amphotericin B methyl ester in dogs. Toxicologic Pathology. 1988;16(1):1-9.
Ellis, W. G. ; Bencken, E. ; LeCouteur, R. A. ; Barbano, J. R. ; Wolfe, Bruce ; Jennings, M. B. / Neurotoxicity of amphotericin B methyl ester in dogs. In: Toxicologic Pathology. 1988 ; Vol. 16, No. 1. pp. 1-9.
@article{d42da351494c45a6a15765547ffd498a,
title = "Neurotoxicity of amphotericin B methyl ester in dogs",
abstract = "Clinical and neuropathologic effects of chronically administered intravenous (iv) amphotericin B methyl ester (AME) were observed in 3 male dogs (2 German shorthaired pointers and 1 pit bull). Each dog received 6.2-7.3 g of AME (299-327 mg/kg body weight) over a period of 11-12 weeks. One dog developed neurologic signs of severe diffuse brain dysfunction and at necropsy all 3 dogs had a marked leukoencephalopathy, most severe in centrum ovale and subcortical white matter of frontal lobes. Brain histopathology included diffuse myelin loss, oligodendrocyte depletion, accumulation of macrophages filled with sudanophilic lipid, fibrillary astrogliosis, and swelling or fragmentation of many axons. Two control dogs administered iv glucose showed no neuropathologic abnormalities. These findings closely resemble the clinical and neuropathologic abnormalities that developed in patients during the first human trial of AME for treatment of fungal infections, but differ from those of animal studies that did not closely simulate the long-term drug administration required for antifungal therapy in humans. It was concluded that before human clinical trial is authorized, experimental protocols for animal studies of drug toxicity should reflect the anticipated human use of the drug, both in dose and duration.",
author = "Ellis, {W. G.} and E. Bencken and LeCouteur, {R. A.} and Barbano, {J. R.} and Bruce Wolfe and Jennings, {M. B.}",
year = "1988",
language = "English (US)",
volume = "16",
pages = "1--9",
journal = "Toxicologic Pathology",
issn = "0192-6233",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Neurotoxicity of amphotericin B methyl ester in dogs

AU - Ellis, W. G.

AU - Bencken, E.

AU - LeCouteur, R. A.

AU - Barbano, J. R.

AU - Wolfe, Bruce

AU - Jennings, M. B.

PY - 1988

Y1 - 1988

N2 - Clinical and neuropathologic effects of chronically administered intravenous (iv) amphotericin B methyl ester (AME) were observed in 3 male dogs (2 German shorthaired pointers and 1 pit bull). Each dog received 6.2-7.3 g of AME (299-327 mg/kg body weight) over a period of 11-12 weeks. One dog developed neurologic signs of severe diffuse brain dysfunction and at necropsy all 3 dogs had a marked leukoencephalopathy, most severe in centrum ovale and subcortical white matter of frontal lobes. Brain histopathology included diffuse myelin loss, oligodendrocyte depletion, accumulation of macrophages filled with sudanophilic lipid, fibrillary astrogliosis, and swelling or fragmentation of many axons. Two control dogs administered iv glucose showed no neuropathologic abnormalities. These findings closely resemble the clinical and neuropathologic abnormalities that developed in patients during the first human trial of AME for treatment of fungal infections, but differ from those of animal studies that did not closely simulate the long-term drug administration required for antifungal therapy in humans. It was concluded that before human clinical trial is authorized, experimental protocols for animal studies of drug toxicity should reflect the anticipated human use of the drug, both in dose and duration.

AB - Clinical and neuropathologic effects of chronically administered intravenous (iv) amphotericin B methyl ester (AME) were observed in 3 male dogs (2 German shorthaired pointers and 1 pit bull). Each dog received 6.2-7.3 g of AME (299-327 mg/kg body weight) over a period of 11-12 weeks. One dog developed neurologic signs of severe diffuse brain dysfunction and at necropsy all 3 dogs had a marked leukoencephalopathy, most severe in centrum ovale and subcortical white matter of frontal lobes. Brain histopathology included diffuse myelin loss, oligodendrocyte depletion, accumulation of macrophages filled with sudanophilic lipid, fibrillary astrogliosis, and swelling or fragmentation of many axons. Two control dogs administered iv glucose showed no neuropathologic abnormalities. These findings closely resemble the clinical and neuropathologic abnormalities that developed in patients during the first human trial of AME for treatment of fungal infections, but differ from those of animal studies that did not closely simulate the long-term drug administration required for antifungal therapy in humans. It was concluded that before human clinical trial is authorized, experimental protocols for animal studies of drug toxicity should reflect the anticipated human use of the drug, both in dose and duration.

UR - http://www.scopus.com/inward/record.url?scp=0023945252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023945252&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 1

EP - 9

JO - Toxicologic Pathology

JF - Toxicologic Pathology

SN - 0192-6233

IS - 1

ER -